Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Cash & Current Investments (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Cash & Current Investments for 5 consecutive years, with $20.2 million as the latest value for Q3 2020.

  • On a quarterly basis, Cash & Current Investments fell 21.03% to $20.2 million in Q3 2020 year-over-year; TTM through Sep 2020 was $20.2 million, a 21.03% decrease, with the full-year FY2019 number at $6.9 million, down 83.0% from a year prior.
  • Cash & Current Investments was $20.2 million for Q3 2020 at Forte Biosciences, down from $27.7 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $76.1 million in Q2 2017 to a low of $4.1 million in Q3 2016.
  • A 5-year average of $24.5 million and a median of $20.2 million in 2020 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 1730.77% in 2017, then tumbled 83.0% in 2019.
  • Forte Biosciences' Cash & Current Investments stood at $5.5 million in 2016, then soared by 552.14% to $35.9 million in 2017, then grew by 13.58% to $40.8 million in 2018, then crashed by 83.0% to $6.9 million in 2019, then soared by 191.11% to $20.2 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Cash & Current Investments are $20.2 million (Q3 2020), $27.7 million (Q2 2020), and $14.2 million (Q1 2020).